Results at Week 56 in a Trial of OZEMPIC Compared to Sitagliptin in Adult Patients with Type 2 Diabetes Mellitus in Combination with Metformin and/or Thiazolidinediones aThe intent-to-treat population includes all randomized and exposed patients
Efficacy is broadly similar between the two formulations, injectable semaglutide is associated with greater reductions in bodyweight, but the difference is not statistically significant 12
The two groups in the study had similar anthropometric characteristics (baseline BMI 29.2 kg/m 2 in the pseudoephedrine treatment group vs 28.5 in the placebo group)
Our Ozempic lawsuit attorneys work with independent medical experts who arent influenced by drug manufacturers marketing
Semaglutide is a drug used to treat type 2 diabetes and sometimes to help tackle obesity
Whats more, traditional compounding pharmacies, led by a licensed pharmacist within a state-licensed pharmacy or federal facility, or by a licensed physician, are exempt from federal Current Good Manufacturing Practice (CGMP) regulations
